ProCE Banner Activity

CME

Emerging Strategies to Optimize Therapeutic Benefit in Gastrointestinal and Lung Cancers

Clinical experts discuss key data in GI and lung malignancies from ASCO 2020 and the optimization of therapeutic benefit through management of cancer cachexia syndrome.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 28, 2020

Expiration: August 27, 2021

No longer available for credit.

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an independent grant from

Helsinn Healthcare SA

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with advanced lung and gastrointestinal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate new and emerging practice-changing therapeutic strategies into the care of patients with advanced gastrointestinal and lung malignancies to optimize clinical outcomes
  • Implement palliative care measures in concert with anticancer therapies to improve quality of life and survival in patients with advanced GI and lung malignancies
  • Proactively manage cancer-related anorexia and cachexia in patients with advanced GI and lung cancers to enable patients to receive maximal benefit from anticancer therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho and salary from Caris and Indivumed.

Staff Disclosure

Staff

Colleen Heffner, PharmD

Colleen Heffner has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 28, 2020, through August 27, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to apply the latest treatment approaches toward the optimal care of patients with advanced gastrointestinal and lung cancer.